Therefore, nanoparticles that are capable of transporting drugs to the diseased region, suppressing and oxygenating Aβ42 fibers, and targeting and inhibiting hyperphosphorylation Tau at the same time will become a potential therapy for AD treatment. This evidence concerns the gene MAPT and Alzheimer disease.